
Mark Stein, PhD, ABPP
Personal Statement
I am clinical psychologist and a Professor of Psychiatry and Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance attention, regulation, and learning) at Seattle Children’s. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s who refer families to PEARL for evaluation and access to our behavioral group treatment programs and treatment recommendations. The PEARL clinic also provided multidisciplinary training for psychologists, psychiatrists, pediatricians, family medicine physicians, and medical students. The majority of my clinical work involves diagnostic evaluations and consultations for the parents, referring physician, and schools. My research emphasis is on personalizing ADHD treatment, and determining how best to combine and sequence interventions throughout the lifespan for individuals with ADHD. I have assisted in the development of several stimulant and non stimulant medications, and participated in many clinical trials. Currently, we are conducting a study for parents with ADHD who have young children with ADHD symptoms where we are treating the parent with medication and behavioral parent training or behavior parent training. I am also investigating the relationship between genetic factors and ADHD treatment response. Other areas of interest include sleep problems and overlap with ADHD, and novel treatments such as Trigeminal Nerve Stimulation (TNS) and augmentation strategies such as mindfulness and physical exercise or activity level.Education
Medical school: Southern Illinois University - Carbondale
Fellowship: MacLean Center for Clinical Medical Ethics, Chicago
Department Affiliations
Centers/Programs
Other Affiliations
PEARL Clinic, Director – Seattle Children’s Hospital
Training Clinic
Center for Child Health, Behavior, and Development
Brotman Baty Institute
Scholarly Expertise
- Adolescent/young adult
- Attention Deficit Disorder (ADD)
- Behavioral genetics
- Child and adolescent psychiatry/psychology
- Collaborative Care / Integrated Care
- Consult psychiatry/psychology
- Developmental neuroscience
- Ethics
- Health services and health policy
- Measurement-based care
- Medically complex
- Outpatient psychiatry/psychology
- Primary care
- Psychiatric specialties
- Randomized controlled trial
- Settings
- Telemedicine
- Telepsychiatry/psychology
Recent Publications
Sequencing Stimulant Medication and Behavioral Parent Training in Multiplex ADHD Families: A Pilot SMART.
(2025 Feb 19)
J Clin Psychiatry 86(1):
Lui JHL, Chronis-Tuscano A, Almirall D, Whitlock KB, French W, Stein MA
(2025 Feb 19)
J Clin Psychiatry 86(1):
Lui JHL, Chronis-Tuscano A, Almirall D, Whitlock KB, French W, Stein MA
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.
(2025 Feb 24)
Cancer Discov
Hugaboom MB, Wirth LV, Street K, Ruthen N, Jegede OA, Schindler NR, Shah V, Zaemes JP, El Ahmar N, Matar S, Savla V, Choueiri TK, Denize T, West DJ, McDermott DF, Plimack ER, Sosman JA, Haas NB, Stein MN, Alter R, Bilen MA, Hurwitz ME, Hammers H, Signoretti S, Atkins MB, Wu CJ, Braun DA
(2025 Feb 24)
Cancer Discov
Hugaboom MB, Wirth LV, Street K, Ruthen N, Jegede OA, Schindler NR, Shah V, Zaemes JP, El Ahmar N, Matar S, Savla V, Choueiri TK, Denize T, West DJ, McDermott DF, Plimack ER, Sosman JA, Haas NB, Stein MN, Alter R, Bilen MA, Hurwitz ME, Hammers H, Signoretti S, Atkins MB, Wu CJ, Braun DA
Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas.
(2025 Jan 23)
Clin Cancer Res
Luke JJ, Sweis RF, Hecht JR, Schneider R, Stein MN, Golan T, Yap TA, Khilnani A, Huang M, Zhao R, Jemielita T, Patel SP
(2025 Jan 23)
Clin Cancer Res
Luke JJ, Sweis RF, Hecht JR, Schneider R, Stein MN, Golan T, Yap TA, Khilnani A, Huang M, Zhao R, Jemielita T, Patel SP
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
(2024 Dec 30)
Nat Commun 15(1): 10743
Stein MN, Dumbrava EE, Teply BA, Gergis US, Guiterrez ME, Reshef R, Subudhi SK, Jacquemont CF, Senesac JH, Bayle JH, Scripture CD, Chatwal MS, Bilen MA, Stadler WM, Becerra CR
(2024 Dec 30)
Nat Commun 15(1): 10743
Stein MN, Dumbrava EE, Teply BA, Gergis US, Guiterrez ME, Reshef R, Subudhi SK, Jacquemont CF, Senesac JH, Bayle JH, Scripture CD, Chatwal MS, Bilen MA, Stadler WM, Becerra CR
Adjuvant therapy in renal cell carcinoma (RCC): progress, at last.
(2024 Nov 30)
Transl Cancer Res 13(11): 6448-6462
Bueno AN, Stein MN, Runcie K
(2024 Nov 30)
Transl Cancer Res 13(11): 6448-6462
Bueno AN, Stein MN, Runcie K
Show complete publication list »